Lantheus Holdings, Inc. (LNTH) fair value analysis

Nasdaq · Updated 2026-09-07

Lantheus Holdings, Inc. is a healthcare company that develops and commercializes diagnostic imaging agents and nuclear medicine products used in medical imaging procedures to help physicians diagnose and treat patients. The company operates globally, with a primary focus on the United States market and international operations serving healthcare providers and patients worldwide.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, LNTH is trading at more than a 25% premium to estimated fair value.

LNTH currently ranks #102 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $101.19
Sector: Healthcare
12-month range: $51.63–$108.96

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Moderate
Margin trend: Contracting
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The top quarter of its range
DCF cross-check: Fairly Valued

What our data shows for LNTH

Our model validated 17 trailing price-to-earnings windows for LNTH, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $51.63–$108.96.
The 14-day relative strength index sits at a neutral 46.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for LNTH
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent LNTH news

TickrTrends' derived news-sentiment signal for LNTH is currently leaning positive, computed from recent coverage.

Lantheus Holdings: Why I Am Exiting Before The Merger Closes (NASDAQ:LNTH) (seekingalpha.com, 2026-08-10)
TickrTrends take: Lantheus Holdings is currently assessed as overvalued by TickrTrends within the Healthcare sector, which suggests the market price may not align with fundamental value metrics at present levels. Given the pending merger referenced in the headline, valuation-focused investors should monitor how deal completion and integration expectations are factored into the stock's current pricing relative to comparable healthcare companies. The combination of an overvalued assessment and merger-related uncertainty creates a backdrop where investors should evaluate whether risk-adjusted returns justify entry or continued positions.
Polaris Global Equity Composite Q2 2026 Commentary (PGVFX) (seekingalpha.com, 2026-07-24)
TickrTrends take: I don't have access to the specific content of the Polaris Global Equity Composite Q2 2026 Commentary or details about what it says regarding LNTH. Without knowing what information about LNTH is actually contained in that commentary, I cannot write factual prose connecting it to the current TickrTrends overvalued assessment. To write accurately for a stock research page, I would need you to provide the relevant details from the commentary that relate to LNTH, such as specific statements about the company's valuation metrics, financial performance, or sector positioning.

What people are saying

Follow the LNTH conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' momentum indicator for LNTH declined from an A rating last week to none this week, representing a meaningful pullback in the stock's directional strength. The stock remains classified as overvalued according to current valuation metrics. This combination of weakening momentum alongside an overvalued status suggests reduced upward pressure on the price in the near term.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is LNTH stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), LNTH is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is LNTH's TickrTrends verdict?

LNTH's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does LNTH compare to other Healthcare stocks?

LNTH ranks #102 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is LNTH overbought or oversold?

LNTH's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

LNTH vs AMGN · LNTH vs BMY · LNTH vs CAH · LNTH vs CDNA · LNTH vs CRL